NCT Number: NCT06707584
Role of MRI in Breast Cancer Subtypes
efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry
Trial opening soon.
Get NotifiedKey information
About this study
2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …): Patient with breast cancer (malignant breast mass) will do MRI breast and molecular subtypes will be assessed
MRI imaging studies will performed on a 1.5 T scanner , The patient is placed in the prone position with both breasts placed adequately in a double breast coil (four-channel phased array coil), MRI sequences are:
- Axial T1WI. 2. Axial T2WI. 3. Axial STIR. 4. DCE-MRI with post-processing subtraction images 5- Axial DWI at b value( 0, 400, 800 and 1000 mm^2 per second) and ADC map will performed 6. MRI spectroscopy MRI acquisition protocol MRI protocols includes
- Axial T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.
- Coronal T2-weighted fast spin echo sequence: TR=3840 ms, TE=81 ms, slice thickness=3.5 mm, and matrix=448×448.s
- Short tau inversion recovery - axial: TR=8540 ms, TE=59 ms, TI=170 ms, slice thickness=3.5 mm, and matrix=320×314.4.
- The standard dynamic protocol commenced with a coronal three-dimensional rapid Field echo (thrive) sense non-enhanced T1-weighted sequence.
- A gadolinium containing contrast was administered at a dose of 0.2 ml/ kg by power injection at a speed of 2.0 ml/s and flushed with 20 ml of saline solution at the same rate.
- Dynamic imaging was then done in five consecutive series at 90-s intervals. Standard subtraction images were obtained by subtracting precontract images from the early peak postcontrast image.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
a. patients with breast cancer confirmed by histopathology,
Exclusion criteria
- breast implants
- general Contraindication of MRI as claustrophobia
Treatment and study plan
Primary outcomes
-
accuracy of MRI in breast cancer subtyping
Time frame: 5 years
To investigate the diagnostic accuracy of dynamic post contrast imaging MRI in evaluation of breast cancer molecular subtypes and DWI and ADC in detection of breast cancer molecular subtypes
Sponsors and collaborators
Lead sponsor
Lamiaa Gomaa Ahmed Elsayed
Other
Registry information
Official study title
Role of MRI in Detection of Breast Cancer Molecular Subtypes in Correlation With Immunohistochemistry Results
Acronym: MRI
Important dates
- Study start
- 2025
- Primary completion
- 2029
- Study completion
- 2030
- First posted
- Nov 27, 2024
- Registry last updated
- Nov 27, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.